

The prolongation effect of ilaprazole-based standard triple therapy for *Helicobacter pylori*: Erratum

In the article, “The prolongation effect of ilaprazole-based standard triple therapy for *Helicobacter pylori*”,^[1] which appears in Volume 99, Issue 38 of *Medicine*, the conflict of interest statement, “The study was funded by Ilyang, which manufactures Ilaprazole”, was left out and has since been added to the article.

Reference

[1] Lee SW, Moon SJ, Kim SH. The prolongation effect of ilaprazole-based standard triple therapy for *Helicobacter pylori*. *Medicine*. 99;38:e22137.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Lee SW, Moon SJ, Kim SH. The prolongation effect of ilaprazole-based standard triple therapy for *Helicobacter pylori*. *Medicine* 2021;100:3 (e24431).

<http://dx.doi.org/10.1097/MD.00000000000024431>